Genetics and Treatment Type Key Factors in Second Cancer Risks Among Childhood Cancer Survivors
New research shows that genetics and therapy type significantly influence the risk of second cancers in childhood cancer survivors, paving the way for personalized follow-up care.
Recent research from St. Jude Children's Research Hospital highlights that the risk of developing a second cancer after childhood cancer treatment is primarily influenced by genetic predisposition and the type of therapy received. Utilizing data from the extensive St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS), scientists have quantified how these factors contribute to secondary cancer risk, which remains the leading cause of mortality among long-term survivors. The study reveals that radiation exposure during treatment is the most significant contributor, accounting for over 40% of secondary cancer risk, prompting a shift toward minimizing radiation doses in modern therapies.
Furthermore, the research uncovers that genetic factors play an influential role, sometimes surpassing the impact of chemotherapy. Using polygenic risk scores—assessments based on common genetic variants—the study found that genetic predispositions could account for up to 37% of the risk for certain second cancers. This is a groundbreaking finding, indicating that genetics should be considered alongside treatment history when assessing survivor risk.
Lifestyle factors such as diet and exercise appear to contribute less to secondary cancer risk at younger ages, with their effects possibly becoming more apparent later in life. Nonetheless, promoting healthy habits remains crucial for overall long-term health.
The findings suggest that personalized follow-up care, including increased screening for those with strong genetic predispositions, could improve early detection and intervention for secondary cancers. This research emphasizes the importance of integrating genetic screening into survivorship care and tailoring treatment strategies to reduce long-term risks.
Overall, this study enhances our understanding of how genetic and treatment-related factors interplay in cancer recurrence, guiding more effective, individualized survivor care to extend life expectancy and improve quality of life.
Source: https://medicalxpress.com/news/2025-05-genetics-therapy-cancer-childhood-treatment.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
'Single shot' malaria vaccine delivery system could transform global immunization
A groundbreaking microcapsule-based vaccine delivery system developed by Oxford scientists could enable single-injection immunization, improving coverage and simplifying vaccination programs worldwide.
Innovative AI Technology Enhances Automated Assessment of Facial Palsy
A new AI system, finely tuned with manual adjustments, offers a promising objective method for assessing facial palsy severity, aiding clinical decision-making and treatment evaluation.
Innovative Rapid and Comfort-Driven Breast Imaging Technology Shows Promise in Early Clinical Trials
A new rapid, pain-free breast imaging system combining photoacoustic and ultrasound technologies shows great potential in early clinical testing, promising improved detection and patient comfort for breast cancer screening.
How Socioeconomic and Environmental Factors Accelerate Population Aging: New Research
A groundbreaking international study uncovers how air pollution, social inequalities, and weak democracies accelerate aging across global populations, highlighting the need for comprehensive public health strategies.